2025-05-15-Jefferies-努瓦伦特（NUVL）_幻灯片数据预览二季度ROS1关键2L+数据以支持2026年获批_44页_3mb

Zidesamtinib (NUVL-520) Clinical and Commercial Analysis

Background:
Zidesamtinib is a ROS1 targeted therapy being developed by Nuvalent for the treatment of ROS1+ NSCLC patients. It is designed to overcome resistance mutations (e.g., G2032R), demonstrate intracranial activity, and maintain a favorable safety profile due to its TRKB sparing mechanism. A Phase 1/2 study (ARROS-1) in 2L+ ROS1+ NSCLC patients reported significant efficacy in heavily pre-treated populations.

Key Findings:

• Efficacy: Data from ESMO24 showed a 44% overall ORR in patients with ≥1 prior ROS1 TKI, and a 41% ORR in patients with ≥2 prior TKIs. Notably, the ORR in patients with ≥2 prior TKIs (41%) was higher than repotrectinib (28%) in a comparable population. The median DOR was 12.1 months for patients with ≥2 prior TKIs, significantly exceeding repotrectinib’s 7.4 months.
• Intracranial Activity: Zidesamtinib demonstrated a 50% iORR in patients with measurable CNS lesions, with no CNS-related AEs reported, outperforming competitors like entrectinib and lorlatinib, which showed higher rates of CNS-related AEs.
• Resistance Mutations: Zidesamtinib showed a high ORR (73%) in patients with prior crizotinib exposure and a competitive iORR (62%) in G2032R mutation patients, exceeding other TKIs.
• Safety: The TRKB sparing design reduced off-target effects, leading to lower rates of GI/CNS AEs compared to competitors (e.g., no dizziness reported vs. 58% for repotrectinib).

Market Opportunity:

• Zidesamtinib has the potential to increase the ROS1+ NSCLC market from ~$500M to ~$1.3B by extending treatment duration (akin to EGFR/ALK inhibitors).
• Nuvalent’s goal is to penetrate the larger first-line market, supported by a registrational cohort in TKI-naïve patients.

Analyst Recommendation:
Jefferies assigns a BUY rating with a price target of $137 (up 93% from current $71), based on its best-in-class profile, potential commercial launch in 2026, and significant market expansion potential.

Key Drivers:

1. Superior efficacy and durability in later lines.
2. Differentiated safety profile.
3. Untapped potential in first-line settings.

Risks:

• Uncertainty in achieving regulatory approvals and commercial launch in 2026.
• Competition from emerging ROS1 TKIs (e.g., taletrectinib).

Conclusion:
Zidesamtinib represents a significant advance in ROS1+ NSCLC treatment with a favorable risk-reward profile. Its unique combination of efficacy, safety, and CNS activity positions it as a potential best-in-class agent across multiple lines of therapy.